Tag Archives: World Health Organization

Patents Not an Issue in the Fight Against Ebola

shutterstock_26191726

As of October 23,2014 more than 4,900 people have died from the current Ebola outbreak, concentrated in the three West African countries of Sierra Leone, Guinea, and Liberia. Frustrated that the process of getting experimental vaccines to West Africa was not moving fast enough, some were quick to blame intellectual property rights. But in reality, as government officials were quick to point out, the WHO first needed to resolve important ethical and safety considerations before a vaccine that Read More >

Patently BIOtech  |  Leave a comment  |  Email This Post
Tags: , , , , , , , , , , , ,

Implementing the WHO PIP Framework – Industry’s Role & Outlook

syringe

In May 2011, the World Health Organization (WHO) adopted the Pandemic Influenza Preparedness (PIP) Framework after nearly five years of contentious negotiations. As noted by Anne Huvos, WHO Secretariat, the two objectives of the PIP Framework are: (1) to improve sharing of influenza viruses with human pandemic potential; and (2) to achieve more predictable, efficient, and equitable access to benefits, such as vaccines and antiviral medicines, during future pandemics. The subject of a session at Read More >

Health  |  Leave a comment  |  Email This Post
Tags: , , , , , , , , , ,

India Compulsory License: A Times of India Article Says It’s Not Helping the Poor

india-btn

India recently issued a compulsory license on Bayer’s liver and kidney cancer drug (Sorafenib) with the stated goal of providing access to India’s poor. However, the Times of India recently ran the article Cheap generics drugs no panacea for India’s poorest, quickly dispelling this myth: “The compulsory license system might not really work because poor people cannot even afford the discounted price,” said G. Balachandhran, former head of the National Pharmaceutical Pricing Authority (NPPA), India’s drug Read More >

Patently BIOtech  |  Leave a comment  |  Email This Post
Tags: , , , , , , , , , , , , ,

If Biotech Builds…Will Financers Come?

Angie Drakulich from PharmaTech Talk writes: In many countries, it’s easy to get the health minister to understand the value of introducing a vaccine and related healthcare training and therapies to his or her population. It’s another thing to get the finance minister to buy into the effort. But healthcare education and training have made and continue to make great inroads into this area. Angie is part of our BIO Official Blog Program. Keep an Read More >

Events  |  Leave a comment  |  Email This Post
Tags: , , , , , , , , ,

Pathogens and the Nagoya Protocol of the Convention on Biological Diversity

          Some nations have argued that the recent Nagoya Protocol of the Convention of Biological Diversity (CBD) includes pathogens. The inclusion of pathogens in the Nagoya Protocol could adversely affect the world’s ability to control outbreaks of infectious disease.  The following reasons demonstrate why pathogens are not and should not be included in the Nagoya Protocol. Contrary to the Mission of the CBD: The three main objectives of the CBD are; “The conservation of biological Read More >

Patently BIOtech  |  Leave a comment  |  Email This Post
Tags: , , , , , , , , , , , , , , , , ,